Published in Haematologica on January 15, 2010
Elucidation of seventeen human peripheral blood B-cell subsets and quantification of the tetanus response using a density-based method for the automated identification of cell populations in multidimensional flow cytometry data. Cytometry B Clin Cytom (2010) 2.38
EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols. Leukemia (2012) 1.60
Advances in human B cell phenotypic profiling. Front Immunol (2012) 1.41
High-resolution antibody dynamics of vaccine-induced immune responses. Proc Natl Acad Sci U S A (2014) 1.39
New criteria for response assessment: role of minimal residual disease in multiple myeloma. Blood (2015) 1.33
Immunosenescence and Challenges of Vaccination against Influenza in the Aging Population. Aging Dis (2011) 1.23
B cell response and hemagglutinin stalk-reactive antibody production in different age cohorts following 2009 H1N1 influenza virus vaccination. Clin Vaccine Immunol (2013) 1.13
Immunophenotyping in multiple myeloma and related plasma cell disorders. Best Pract Res Clin Haematol (2010) 1.08
Characterization of plasmablasts in the blood of HIV-infected viremic individuals: evidence for nonspecific immune activation. J Virol (2013) 1.06
Effects of aging on human leukocytes (part II): immunophenotyping of adaptive immune B and T cell subsets. Age (Dordr) (2015) 1.04
Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry. Haematologica (2012) 1.04
IL-6 supports the generation of human long-lived plasma cells in combination with either APRIL or stromal cell-soluble factors. Leukemia (2014) 1.02
Thymic and bone marrow output in patients with common variable immunodeficiency. J Clin Immunol (2011) 0.99
Comparison of memory B cell, antibody-secreting cell, and plasma antibody responses in young children, older children, and adults with infection caused by Vibrio cholerae O1 El Tor Ogawa in Bangladesh. Clin Vaccine Immunol (2011) 0.98
Human lymphocyte repertoires in ageing. Curr Opin Immunol (2013) 0.98
CD117 expression in gammopathies is associated with an altered maturation of the myeloid and lymphoid hematopoietic cell compartments and favorable disease features. Haematologica (2010) 0.96
Optimization and qualification of a memory B-cell ELISpot for the detection of vaccine-induced memory responses in HIV vaccine trials. J Immunol Methods (2013) 0.90
The majority of human memory B cells recognizing RhD and tetanus resides in IgM+ B cells. J Immunol (2014) 0.87
Circulating clonotypic B cells in multiple myeloma and monoclonal gammopathy of undetermined significance. Haematologica (2013) 0.85
Preexisting Immunity, More Than Aging, Influences Influenza Vaccine Responses. Open Forum Infect Dis (2015) 0.85
B cell responses to the 2011/12-influenza vaccine in the aged. Aging (Albany NY) (2013) 0.84
The protein tyrosine phosphatase PTP1B is a negative regulator of CD40 and BAFF-R signaling and controls B cell autoimmunity. J Exp Med (2014) 0.83
Frequency and phenotype of B cell subpopulations in young and aged HIV-1 infected patients receiving ART. Retrovirology (2014) 0.83
GenomicScape: an easy-to-use web tool for gene expression data analysis. Application to investigate the molecular events in the differentiation of B cells into plasma cells. PLoS Comput Biol (2015) 0.83
Differential effects of lenalidomide during plasma cell differentiation. Oncotarget (2016) 0.82
Differential effects of Cytomegalovirus carriage on the immune phenotype of middle-aged males and females. Sci Rep (2016) 0.81
Proportions of CD4+, CD8+ and B cell subsets are not affected by exposure to HIV or to Cotrimoxazole prophylaxis in Malawian HIV-uninfected but exposed children. BMC Immunol (2015) 0.80
Residual malignant and normal plasma cells shortly after high dose melphalan and stem cell transplantation. Highlight of a putative therapeutic window in Multiple Myeloma? Oncotarget (2012) 0.80
Immune defects in the risk of infection and response to vaccination in monoclonal gammopathy of undetermined significance and multiple myeloma. Front Immunol (2014) 0.79
Absence of immune responses with xenogeneic collagen and elastin. Tissue Eng Part A (2013) 0.79
Multiparameter flow cytometry and bioanalytics for B cell profiling in systemic lupus erythematosus. Methods Mol Biol (2012) 0.78
Identification of microRNAs implicated in the late differentiation stages of normal B cells suggests a central role for miRNA targets ZEB1 and TP53. Oncotarget (2017) 0.77
Mass cytometry analysis shows that a novel memory phenotype B cell is expanded in multiple myeloma. Cancer Immunol Res (2015) 0.77
Altered distribution of peripheral blood memory B cells in humans chronically infected with Trypanosoma cruzi. PLoS One (2014) 0.77
Reply to “Response to “CD20 positive cells are undetectable in the majority of multiple myeloma cell lines and are not associated with a cancer stem cell phenotype”. Haematologica 2012;97(7):1110-1114. Haematologica (2013) 0.77
Natural Antibodies as Rheostats for Susceptibility to Chronic Diseases in the Aged. Front Immunol (2016) 0.76
Human CD38hiCD138⁺ plasma cells can be generated in vitro from CD40-activated switched-memory B lymphocytes. J Immunol Res (2014) 0.76
Epithelial IL-1R2 acts as a homeostatic regulator during remission of ulcerative colitis. Mucosal Immunol (2015) 0.76
Validation and implementation of a method for microarray gene expression profiling of minor B-cell subpopulations in man. BMC Immunol (2014) 0.76
Mobilization of plasma cells in healthy individuals treated with granulocyte colony-stimulating factor for haematopoietic stem cell collection. Immunology (2010) 0.76
Multiple myeloma cell lines and primary tumors proteoma: protein biosynthesis and immune system as potential therapeutic targets. Genes Cancer (2015) 0.75
Kruppel-like factor4 regulates PRDM1 expression through binding to an autoimmune risk allele. JCI Insight (2017) 0.75
Development of Plasmodium falciparum specific naïve, atypical, memory and plasma B cells during infancy and in adults in an endemic area. Malar J (2017) 0.75
Massive plasmablast response elicited in the acute phase of Hantavirus Pulmonary Syndrome. Immunology (2017) 0.75
High Levels of (Un)Switched Memory B Cells Are Associated With Better Outcome in Patients With Advanced Atherosclerotic Disease. J Am Heart Assoc (2017) 0.75
Antigen-specific immunotherapies in rheumatic diseases. Nat Rev Rheumatol (2017) 0.75
Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches. Immunity (2006) 11.28
Haematopoietic stem cell release is regulated by circadian oscillations. Nature (2008) 6.50
Lymphocyte subsets in healthy children from birth through 18 years of age: the Pediatric AIDS Clinical Trials Group P1009 study. J Allergy Clin Immunol (2003) 5.43
Competence and competition: the challenge of becoming a long-lived plasma cell. Nat Rev Immunol (2006) 5.22
Immunosurveillance by hematopoietic progenitor cells trafficking through blood, lymph, and peripheral tissues. Cell (2007) 5.17
B lymphocytes: how they develop and function. Blood (2008) 4.07
Identification and characterization of circulating human transitional B cells. Blood (2005) 3.62
Generation of migratory antigen-specific plasma blasts and mobilization of resident plasma cells in a secondary immune response. Blood (2004) 3.17
Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders. Haematologica (2008) 2.99
B-cell responses to vaccination at the extremes of age. Nat Rev Immunol (2009) 2.50
Dendritic cells and monocyte/macrophages that create the IL-6/APRIL-rich lymph node microenvironments where plasmablasts mature. J Immunol (2009) 2.39
Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma. Blood (1994) 2.10
Novel human transitional B cell populations revealed by B cell depletion therapy. J Immunol (2009) 2.05
Blood-borne human plasma cells in steady state are derived from mucosal immune responses. Blood (2008) 1.91
An in vitro model of differentiation of memory B cells into plasmablasts and plasma cells including detailed phenotypic and molecular characterization. Blood (2009) 1.86
Memory B cells: effectors of long-lived immune responses. Eur J Immunol (2009) 1.74
Identification and characterization of a human CD5+ pre-naive B cell population. J Immunol (2009) 1.59
Mechanisms for decreased function of B cells in aged mice and humans. J Immunol (2008) 1.31
Transitional B cells in humans: characterization and insight from B lymphocyte reconstitution after hematopoietic stem cell transplantation. Clin Immunol (2008) 1.26
Normal and malignant human plasma cells: proliferation, differentiation, and expansions in relation to CD45 expression. Blood Cells Mol Dis (2004) 1.25
The Mi15 monoclonal antibody (anti-syndecan-1) is a reliable marker for quantifying plasma cells in paraffin-embedded bone marrow biopsy specimens. Hum Pathol (1999) 1.20
APRIL and TACI interact with syndecan-1 on the surface of multiple myeloma cells to form an essential survival loop. Eur J Haematol (2009) 1.17
A study of serum immunoglobulin levels in elderly persons that provides new insights into B cell immunosenescence. Ann N Y Acad Sci (2006) 1.01
Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. N Engl J Med (2013) 6.21
A meta-analysis of human embryonic stem cells transcriptome integrated into a web-based expression atlas. Stem Cells (2007) 3.62
Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clin Cancer Res (2003) 3.10
Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders. Haematologica (2008) 2.99
Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference. Leuk Res (2007) 2.97
BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood (2003) 2.82
Cancer stem cell definitions and terminology: the devil is in the details. Nat Rev Cancer (2012) 2.76
Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood (2008) 2.74
Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma. J Natl Cancer Inst (2006) 2.69
RNA interference in vitro and in vivo using a novel chitosan/siRNA nanoparticle system. Mol Ther (2006) 2.59
Generation of polyclonal plasmablasts from peripheral blood B cells: a normal counterpart of malignant plasmablasts. Blood (2002) 2.48
Mixed-phenotype acute leukemia: clinical and laboratory features and outcome in 100 patients defined according to the WHO 2008 classification. Blood (2011) 2.14
International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood (2011) 2.13
The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature. Blood (2005) 1.96
Granulocyte-macrophage colony-stimulating factor potentiates rituximab in patients with relapsed follicular lymphoma: results of a phase II study. J Clin Oncol (2008) 1.87
Gene expression profiling of plasma cells and plasmablasts: toward a better understanding of the late stages of B-cell differentiation. Blood (2003) 1.87
An in vitro model of differentiation of memory B cells into plasmablasts and plasma cells including detailed phenotypic and molecular characterization. Blood (2009) 1.86
Embryonic stem cell markers expression in cancers. Biochem Biophys Res Commun (2009) 1.84
A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines. Haematologica (2010) 1.80
Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma. J Clin Oncol (2011) 1.78
Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). Blood (2011) 1.75
Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma. Haematologica (2010) 1.73
Intensive therapy for multiple myeloma in patients younger than 60 years. Long-term results focusing on the effect of the degree of response on survival and relapse pattern after transplantation. Haematologica (2006) 1.68
Heparanase influences expression and shedding of syndecan-1, and its expression by the bone marrow environment is a bad prognostic factor in multiple myeloma. Blood (2007) 1.65
Suppression of p21Rac signaling and increased innate immunity mediate remission in Crohn's disease. Sci Transl Med (2014) 1.64
Zinc-finger transcription factor Slug contributes to the function of the stem cell factor c-kit signaling pathway. Blood (2002) 1.64
Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal. Int Arch Allergy Immunol (2011) 1.63
Expanded cells in monoclonal TCR-alphabeta+/CD4+/NKa+/CD8-/+dim T-LGL lymphocytosis recognize hCMV antigens. Blood (2008) 1.61
The human cumulus--oocyte complex gene-expression profile. Hum Reprod (2006) 1.60
A gene expression signature shared by human mature oocytes and embryonic stem cells. BMC Genomics (2009) 1.58
Possible roles for activating RAS mutations in the MGUS to MM transition and in the intramedullary to extramedullary transition in some plasma cell tumors. Blood (2004) 1.57
Differences in anti-apoptotic and multidrug resistance phenotypes in elderly and young acute myeloid leukemia patients are related to the maturation of blast cells. Haematologica (2005) 1.56
A major role for Mcl-1 antiapoptotic protein in the IL-6-induced survival of human myeloma cells. Oncogene (2003) 1.54
Prognostic value of immunophenotyping in multiple myeloma: a study by the PETHEMA/GEM cooperative study groups on patients uniformly treated with high-dose therapy. J Clin Oncol (2008) 1.53
Comparison of gene expression profiling between malignant and normal plasma cells with oligonucleotide arrays. Oncogene (2002) 1.53
Cancer induction by restriction of oncogene expression to the stem cell compartment. EMBO J (2008) 1.52
The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor. Blood (2009) 1.51
Treatment of relapsed and refractory multiple myeloma in the era of novel agents. Cancer Treat Rev (2010) 1.48
Clinical, biological, and molecular characteristics of clonal mast cell disorders presenting with systemic mast cell activation symptoms. J Allergy Clin Immunol (2010) 1.46
Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disorders. Haematologica (2012) 1.45
Different subsets of peripheral blood dendritic cells show distinct phenotypic and functional abnormalities in HIV-1 infection. AIDS (2005) 1.44
Expression of EGF-family receptors and amphiregulin in multiple myeloma. Amphiregulin is a growth factor for myeloma cells. Oncogene (2005) 1.44
CD200 is a new prognostic factor in multiple myeloma. Blood (2006) 1.44
Importance of granulocyte colony-stimulating factor prophylaxis in therapy with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone given every 14 days for diffuse large B-cell lymphoma in routine clinical practice. Leuk Lymphoma (2012) 1.42
Characterization of a transitional preplasmablast population in the process of human B cell to plasma cell differentiation. J Immunol (2011) 1.42
Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes. Haematologica (2009) 1.40
Importance of [18F]fluorodeoxyglucose-positron emission tomography scanning for the monitoring of responses to immunotherapy in follicular lymphoma. Leuk Lymphoma (2007) 1.40
Bioactivity and prognostic significance of growth differentiation factor GDF15 secreted by bone marrow mesenchymal stem cells in multiple myeloma. Cancer Res (2012) 1.38
Utility of flow cytometry immunophenotyping in multiple myeloma and other clonal plasma cell-related disorders. Cytometry B Clin Cytom (2010) 1.36
Cancer/testis genes in multiple myeloma: expression patterns and prognosis value determined by microarray analysis. J Immunol (2007) 1.32
Genome wide transcriptional analysis of resting and IL2 activated human natural killer cells: gene expression signatures indicative of novel molecular signaling pathways. BMC Genomics (2007) 1.30
Effective dose of CT- and fluoroscopy-guided perineural/epidural injections of the lumbar spine: a comparative study. Cardiovasc Intervent Radiol (2006) 1.29
The progression from MGUS to smoldering myeloma and eventually to multiple myeloma involves a clonal expansion of genetically abnormal plasma cells. Clin Cancer Res (2011) 1.28
Prognostic and biologic significance of chromosomal imbalances assessed by comparative genomic hybridization in multiple myeloma. Blood (2004) 1.26
SHIP1 inhibition increases immunoregulatory capacity and triggers apoptosis of hematopoietic cancer cells. J Immunol (2010) 1.25
Intracoronary autologous mononucleated bone marrow cell infusion for acute myocardial infarction: results of the randomized multicenter BONAMI trial. Eur Heart J (2010) 1.23
Induction of angiogenesis by normal and malignant plasma cells. Blood (2009) 1.22
The nature of circulating CD27+CD43+ B cells. J Exp Med (2011) 1.22
Mast cells from different molecular and prognostic subtypes of systemic mastocytosis display distinct immunophenotypes. J Allergy Clin Immunol (2010) 1.22
Embryonic stem cell grafting in normal and infarcted myocardium: serial assessment with MR imaging and PET dual detection. Radiology (2009) 1.21
Genetic abnormalities and patterns of antigenic expression in multiple myeloma. Clin Cancer Res (2005) 1.21
Identification of leptomeningeal disease in aggressive B-cell non-Hodgkin's lymphoma: improved sensitivity of flow cytometry. J Clin Oncol (2009) 1.21
Bone marrow stromal cell interaction reduces syndecan-1 expression and induces kinomic changes in myeloma cells. Exp Cell Res (2010) 1.21
Conventional diagnostics in multiple myeloma. Eur J Cancer (2006) 1.20
Cancer development induced by graded expression of Snail in mice. Hum Mol Genet (2005) 1.18
Targeting NF-kappaB pathway with an IKK2 inhibitor induces inhibition of multiple myeloma cell growth. Br J Haematol (2007) 1.17
APRIL and TACI interact with syndecan-1 on the surface of multiple myeloma cells to form an essential survival loop. Eur J Haematol (2009) 1.17
Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma. Blood (2009) 1.16
Generation of flow cytometry data files with a potentially infinite number of dimensions. Cytometry A (2008) 1.16
Prognosis in adult indolent systemic mastocytosis: a long-term study of the Spanish Network on Mastocytosis in a series of 145 patients. J Allergy Clin Immunol (2009) 1.15
Detailed characterization of multiple myeloma circulating tumor cells shows unique phenotypic, cytogenetic, functional, and circadian distribution profile. Blood (2013) 1.15
Flow cytometry detection of minimal residual disease in multiple myeloma: Lessons learned at FDA-NCI roundtable symposium. Am J Hematol (2014) 1.15
CD20 positive cells are undetectable in the majority of multiple myeloma cell lines and are not associated with a cancer stem cell phenotype. Haematologica (2012) 1.14
Identification of a new HLA-A2-restricted T-cell epitope within HM1.24 as immunotherapy target for multiple myeloma. Exp Hematol (2006) 1.14
Immunogenetics shows that not all MBL are equal: the larger the clone, the more similar to CLL. Blood (2013) 1.14
Dermoscopic features of skin lesions in patients with mastocytosis. Arch Dermatol (2011) 1.14
Risk of progression in smouldering myeloma and monoclonal gammopathies of unknown significance: comparative analysis of the evolution of monoclonal component and multiparameter flow cytometry of bone marrow plasma cells. Br J Haematol (2009) 1.13
Microarray-based understanding of normal and malignant plasma cells. Immunol Rev (2006) 1.12
A novel molecular mechanism involved in multiple myeloma development revealed by targeting MafB to haematopoietic progenitors. EMBO J (2012) 1.12
RCL2, a new fixative, preserves morphology and nucleic acid integrity in paraffin-embedded breast carcinoma and microdissected breast tumor cells. J Mol Diagn (2006) 1.12
Bone marrow cells from myelodysplastic syndromes show altered immunophenotypic profiles that may contribute to the diagnosis and prognostic stratification of the disease: a pilot study on a series of 56 patients. Cytometry B Clin Cytom (2010) 1.12
Impact of age on survival after intensive therapy for multiple myeloma: a population-based study by the Nordic Myeloma Study Group. Br J Haematol (2006) 1.11
A new method for class prediction based on signed-rank algorithms applied to Affymetrix microarray experiments. BMC Bioinformatics (2008) 1.11
Randomized phase II study of bortezomib, thalidomide, and dexamethasone with or without cyclophosphamide as induction therapy in previously untreated multiple myeloma. J Clin Oncol (2012) 1.10
[Diagnosis and treatment of nocturnal paroxysmal hemoglobinuria]. Med Clin (Barc) (2010) 1.10
Flow cytometry criteria for systemic mastocytosis: bone marrow mast cell counts do not always count. Am J Clin Pathol (2013) 1.10
Quantitative analysis of the expression of glycosylphosphatidylinositol-anchored proteins during the maturation of different hematopoietic cell compartments of normal bone marrow. Cytometry B Clin Cytom (2007) 1.10
MMSET is overexpressed in cancers: link with tumor aggressiveness. Biochem Biophys Res Commun (2008) 1.09